Filter By Category
Archives
Share on -
DUVORTUXIZUMAB
Generic Name: DUVORTUXIZUMAB
ABSTRACT -
Duvortuxizumab is an investigational CD19 x CD3 bispecific antibody-like DART protein designed to redirect T cells against CD19-positive B-cell malignancies.
DOSAGE -
No approved dosage. Administered in specialized oncology trials using step-up or protocol-defined dosing when applicable.
SIDE EEFECTS -
- Cytokine release syndrome
- Fever or chills
- Neurotoxicity symptoms
- Cytopenias
- Infections
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Infusion hypersensitivity
- Rash or urticaria
- Hypotension or bronchospasm
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Immunosuppressants may reduce T-cell engagement activity
- Other T-cell activating therapies may increase cytokine toxicity
- Avoid live vaccines during immune suppression
PREAUTONS–
- Specialist oncology setting required
- Monitor for CRS, neurotoxicity, cytopenias, and infection
- Premedication and step-up dosing may be protocol-required
WARNINGS –
- Potentially serious CRS and neurotoxicity
- Investigational; not for routine clinical use
Share on -
. Developed by